Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading higher on Wednesday, with apparently no news to justify the movement.This week, Sarepta will present data from its gene therapy, delandistrogene moxeparvovec, for Duchenne muscular dystrophy (DMD).Sarepta presentations will include results from several studies in the delandistrogene moxeparvovec clinical development program and a real-world evidence study of pulmonary function in advanced-stage patients with Duchenne muscular dystrophy treated with ca ...